Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer
25.11.2025 09:00:00 CET | Business Wire | Press Release
Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/
Digital assets – including cryptocurrencies, stablecoins and tokenised financial instruments, all built upon blockchain technology – are an increasingly important part of the global financial system. As adoption accelerates, regulation is driving vast demand for independent, institutional-grade assurance services to strengthen transparency and safeguard investors.
ht.digital is the leading digital asset transparency layer. From proof of reserves and attestations to financial audit, corporate finance and operations, they have developed a global presence with over 700 clients worldwide. Combining blockchain expertise, accounting knowledge and operational know-how with proprietary tools for on-chain verification, reconciliation and reporting, their role in enabling digital asset issuers to access institutional demand continues to expand.
Since the business was carved-out from Harris & Trotter LLP in 2023, it has established itself as the category leader in this emerging segment, with near-100% organic revenue CAGR over the last two years, underpinned by wins across exchanges, blockchain platforms and institutional clients. ht.digital operates in a sizeable market that is forecast to grow rapidly and is positioned to benefit from increased institutional adoption and regulatory demand for independent assurance.
Bridgepoint’s investment will support ht.digital as it scales internationally and further professionalises its platform, building on its recent expansion into Europe. The partnership will enable continued investment in the firm’s product and data innovation, alongside recruitment of specialist talent to add to its existing high-calibre team.
Matt Legg, Partner at Bridgepoint, said: “ht.digital sits at the intersection of two powerful, long-term trends — the institutional adoption of digital assets and the growing regulatory demand for independent audit and assurance. Nick and his team have built an exceptional business that combines accounting rigour, crypto-native expertise and advanced automation to deliver trusted assurance in a rapidly evolving market. We’re delighted to partner with them to help realise ht.digital’s potential as the global leader in its field.”
Nick Newman, Founder and CEO of ht.digital, added: “Today is an important milestone for ht.digital. I’m immensely proud of what our team has built and grateful to our clients, my partners and Harris & Trotter for their support on the journey. Bridgepoint understands our business and knows how to scale professional services and technology firms. They are the ideal partner for ht.digital’s growth ambitions as we invest in our platform and expand internationally.”
Bridgepoint was advised by Bain (Commercial), Cleary Gottlieb (Legal), EY (Financial & Tax), Areta (M&A) and Achilles (ESG).
ht.digital was advised by Arrowpoint Advisory (Corporate Finance), Roland Berger (Commercial) and Dentons (Legal).
The transaction is expected to complete in H1 2026, subject to customary regulatory approvals. Financial terms were not disclosed.
About Bridgepoint
Bridgepoint Group is one of the world's leading mid-market investors, specialising in private equity, infrastructure and private credit.
With $87 billion of assets under management and a strong local presence in Europe, North America and Asia, we combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles.
About ht.digital
ht.digital is a London-headquartered specialist in digital asset transparency, providing audit, assurance, accounting, operations and technology services; formed in 2023 through the carve-out of Harris & Trotter LLP’s digital assets practice. The firm serves over 700 clients worldwide, including blockchain protocols, infrastructure, exchanges, custodians and traditional financial institutions. ht.digital combines deep accounting and crypto expertise with proprietary automation for real-time, on-chain verification, reconciliation and reporting, including proof of reserves and attestations. The firm is registered with the ICAEW and delivers cross-border work across the UK, EU, Middle East, APAC and the Americas.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251125907148/en/
Contacts
Tom Clark
tom.clark@bridgepoint.eu
07767 786852
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom